Peresolimab Demonstrates Efficacy in Treating Patients With Rheumatoid Arthritis

At the 12-week mark, the change from baseline in the DAS28-CRP was significantly greater in patients with rheumatoid arthritis receiving 700 mg peresolimab when compared with the placebo group.

Related Keywords

Ajay Nirula ,Eli Lilly ,Company Ajay Nirula ,American College Of Rheumatology ,New England Journal ,American College ,Disease Activity Score ,Clinical Disease Activity Index ,